Year: 2007
Type: letter
Abstract: respectively), and that infections were the main cause of toxic deaths in both treatment arms, caution is required when using DCF in a standard (elderly) population of patients with advanced gastric cancer.We do not know what the rate of toxic deaths would have been for DCF if the patients included in this trial would have met the median age of 70 years, as in the average population of gastric cancer patients.Thus, results of V325 are only valid for a patient population similar to that of the trial cohort.Further data to evaluate the risk/benefit ratio for the use of DCF in elderly patients with advanced gastric cancer is required.
Source: Journal of Clinical Oncology
Author: Jaffer A. Ajani
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2623454034